These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration. Park DH; Sun HJ; Lee SJ Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933 [TBL] [Abstract][Full Text] [Related]
7. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes. Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration. Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055 [TBL] [Abstract][Full Text] [Related]
9. Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections. Rasmussen A; Sander B; Larsen M; Brandi S; Fuchs J; Hansen LH; Lund-Andersen H Acta Ophthalmol; 2017 Mar; 95(2):128-132. PubMed ID: 27535819 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration. Matsumoto H; Hiroe T; Morimoto M; Mimura K; Ito A; Akiyama H Jpn J Ophthalmol; 2018 Mar; 62(2):144-150. PubMed ID: 29411171 [TBL] [Abstract][Full Text] [Related]
11. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD. Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756 [TBL] [Abstract][Full Text] [Related]
12. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor. Moon DRC; Lee DK; Kim SH; You YS; Kwon OW Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506 [TBL] [Abstract][Full Text] [Related]
14. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study. Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339 [TBL] [Abstract][Full Text] [Related]
15. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness. Shah CP; Heier JS Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479 [TBL] [Abstract][Full Text] [Related]
16. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration. Yun C; Oh J; Ahn J; Hwang SY; Lee B; Kim SW; Huh K Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1693-702. PubMed ID: 26781585 [TBL] [Abstract][Full Text] [Related]
17. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. Lotfy A; Solaiman KAM; Abdelrahman A; Samir A Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552 [TBL] [Abstract][Full Text] [Related]
18. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol. Jørstad ØK; Faber RT; Moe MC Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485 [TBL] [Abstract][Full Text] [Related]